Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radiation boost may supercharge CAR T-Cell therapy against tough lymphoma

NCT ID NCT07676877

Not yet recruiting Disease control Sponsor: Nathan Denlinger Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This trial tests whether adding low-dose total body irradiation (TBI) to standard chemotherapy before CAR T-cell therapy (tisagenlecleucel) is safe and effective for adults with large B-cell lymphoma that has returned or not responded to prior treatments. The study involves 18 participants and aims to find the best dose of TBI that can be given safely. If it works, this approach could help more patients achieve remission.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
low-dose total body irradiation plus tisagenlecleucel (CAR T-cell therapy)
What this could lead to
If successful, this combination could improve the effectiveness of CAR T-cell therapy for patients with hard-to-treat large B-cell lymphoma.
What could go wrong
This is an early-phase trial with only 18 participants, so results may not apply broadly. Adding radiation may increase side effects like low blood counts or organ toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.